ABSTRACT
0.05).CONCLUSION: There is no pharmacoeconomic difference between aripiprazol and risperidone in the treatment schizophrenia.
ABSTRACT
OBJECTIVE:To observe the efficacy and safety of sertraline combined with Shumian capsule for depression of dyssomnia.METHODS:86 patients with depression were randomly assigned to receive sertraline alone(single group) or in combination with Shumian capsule(combined group) for 8 weeks.Clinical effectiveness was evaluated using HAMD and PSQI,and TESS was used to assess the adverse effects.RESULTS:After treatment for 8 weeks,the total effective rate was 88.2% for combined group and 85.7% for single group(P
ABSTRACT
OBJECTIVE:To evaluate the pharmacoeconomics effectiveness of venlafaxine combined with quetiapine in the treatment of treatment-resistant depression.METHODS:74 patients with treatment-resistant depression were randomly divided into treatment group(n=38) and control group(n=36).Clinical efficacies of 2 groups were evaluated at baseline and the end of 12 weeks treatment using Hamilton Rating Scale for Depression(HAMD).The total cost of the two groups was calculated and cost-effectiveness analysis was carried out.RESULTS:The per capita cost of treatment group and control group were 1 688.69 and 1487.22 yuan.The HAMD reduction score of 2 groups were 14.5 and 10.2 and the C/E of 2 groups were 116.46 and 145.81,respectively.CONCLUSION:Venlafaxine combine with quetiapine is more economical and practical than venlafaxine alone in the treatment of treatment-resistant depression.
ABSTRACT
OBJECTIVE:To analyze the cost-effectiveness of3kinds of Chinese patent drugs in the treatment of insomnia outpatients.METHODS:78outpatients with insomnia were randomly divided into group A,group B and group C,and they were treated with shumian capsule,sweet dream capsule and compound semen ziziphi spinosae capsule,respectively,then,cost-effectiveness analysis was carried out with pharmacoeconomics.RESULTS:The per capita costs(C)for group A,B and C were288.20yuan,163.08yuan and139.22yuan respectively,the reduction in PSQI scores(E 1 )were5.15,8.88and11.84respectively,the effective rates(E 2 )were26%,46%,and64%respectively;The average cost-effect ratios C/E 1 were55.96,18.36,and11.76respectively;C/E 2 were11.08,3.55,and2.18respectively;The increment of the cost-effect ratios?C/?E 1 for group A and B were—22.27and—8.06respectively;?C/?E 2 were—3.92,—1.33respectively,as compared with group C.CONCLUSION:Compound semen ziziphi spinosae capsule is more economical in3drugs in treating insomnia outpatients.
ABSTRACT
Objective : To evaluate the efficacy and safety of Morita therapy combined with citalopram in the treatment of obsessive-compulsive disorder(OCD). Methods: Fifty-six patients with OCD were randomized to two groups. The patients (N=28 ) in observed group were treated with Morita therapy combined with citalopram. The patients (N=28 ) in control group were treated with citalopram alone. The efficacy and safety were assessed with Y-BOCS, CGI-SI , HAMD and TESS scales. Results : The scores of Y-BOCS , CGI-SI and HAMD scales in observed group were significantly lower than that in control group at the end of 4 weeks, 8 weeks and 6 month after the treatment (P0.05) . Conclusion: Morita therapy combined with citalopram was more effective than citalopram mono-therapy in the treatment of OCD.
ABSTRACT
OBJECTIVE:To observe the efficacy and adverse reaction of venlafaxine combined with Bailemian capsule for somatization disorder.METHODS:145 patients with somatization disorder were randomly assigned to receive venlafaxine alone (single group) or in combination with Bailemian capsule (combined group) for 8 weeks.Clinical global impression scale (CGI) and symptom check (SCL-90) were used to assess the efficacy and treatment emergent symptom scale (TESS) was used to assess the adverse reactions.RESULTS:After 8 weeks of treatment,CGI score showed the total effective rate were 88.14% for single group and 94.18% for combined group (P
ABSTRACT
OBJECTIVE:To evaluate the cost-effectiveness of two therapeutic schemes in the treatment of the first at?tack of schizophrenia.METHODS:206inpatients with schizophrenia were randomly assigned to receive antipsychotics plus cognitive behavior therapy(scheme A)or to receive antipsychotics alone(scheme B),the cost-effectiveness of the two schemes was analyzed by the theory of pharmacoeconomics.RESULTS:The costs for scheme A and B were(4460.68?1034.33)yuan and(3883.32?853.46)yuan respectively(P
ABSTRACT
OBJECTIVE:To study the econamics effect of risperidone and quetiapine in treating of schizophrenia.METH ODS:64schizophrenia patients were randomly divided into risperidone group(34cases)and quetiapine group(30cases).The effects were evaluated based on the reduction of scores determined by brief psychiatric rating scale(BPRS);the adverse effects were evaluated by treatment emergent symptom scale(TESS).And then the cost-effectiveness analysis was carried through.RESULTS:The per capita costs for risperidone and quetiapine were3598.85yuan and3778.63yuan respectively;the re-duction of BPRS scores were(36.09?15.52)and(25.03?14.45)respectvely;the respective cost-effect ratio was99.72yuan and150.96yuan;the increment of the cost-effect ratio for the quetiapine group was-16.25compared with the risperidone group.CONCLUSION:Risperidone is more economical than quetiapine in the treatment of schizophrenia.
ABSTRACT
AIM:To evaluate the efficacy of Bailemian Capsule(bulbus lilii,Radix et rhizome seu acanthopanacis senticosi caulis,Caulis polygoni multiflori,Flos albiziae,Concha margaritifera) in combination with buspirone in generalised anxiety disease. METHODS:Seventy-seven patients with generalized anxiety disease were randomly assigned to two groups:Bailemian Capsule in combination with buspirone in the treated group; buspirone alone in the control group. A period of six weeks was one treatment course in each group. The clinical effectiveness was evaluated according to HAMA reactions. RESULTS:HAMA score(P